Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 3Carcinoma, Hepatocellular 3Prostatic Neoplasms 2Liver Neoplasms 2Hemangiosarcoma 2Glioma 2Choriocarcinoma 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Trophoblastic Tumor, Placental Site 1Sarcoma 1Ovarian Neoplasms 1Oligodendroglioma 1Neoplasms 1Liver Neoplasms, Experimental 1Gliosarcoma 1Gestational Trophoblastic Disease 1Fallopian Tube Neoplasms 1Disease Progression 1Carcinoma, Transitional Cell 1Brain Neoplasms 1Astrocytoma 1Adult Solid Tumor 1Adenoma, Liver Cell 1

Interventions

Lenalidomide 3Bortezomib 3Dexamethasone 2vandetanib 1umbralisib 1ublituximab 1marizomib 1durvalumab 1carotuximab 1avelumab 1Zoledronic Acid 1Vitamin D 1Transplantation, Autologous 1Tamoxifen 1Standard of Care 1Practice Guidelines as Topic 1Palliative Care 1Oxaliplatin 1Melphalan 1Leucovorin 1Irinotecan 1Granulocyte Colony-Stimulating Factor 1Gemcitabine 1Folfox protocol 1Fluorouracil 1Filgrastim 1Cyclophosphamide 1Cisplatin 1Carboplatin 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Disease Progression × carotuximab × Clear all
NCT01778530 2015-10-07

TRC105 for Recurrent Glioblastoma

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
2 enrolled 9 charts
CNS

Glioblastoma, Glioma, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡